Back to Search
Start Over
First-line PD-1/PD-L1 inhibitor followed by carboplatin (carbo)-based chemotherapy (chemo) or the reverse sequence in cisplatin-ineligible metastatic urothelial cancer (mUC) patients (pts)
- Source :
- Journal of Clinical Oncology. 36:e16517-e16517
- Publication Year :
- 2018
- Publisher :
- American Society of Clinical Oncology (ASCO), 2018.
-
Abstract
- e16517Background: PD-1/PD-L1 inhibitors or carbo-based chemo are both reasonable therapeutic options in the first-line setting for cisplatin-ineligible mUC pts. However, optimal first-line therapy and sequencing of these regimens is unclear. Methods: We conducted a multicenter retrospective analysis of cisplatin-ineligible mUC pts treated with first-line PD-1/PD-L1 monotherapy followed by carbo-based chemo (P- > C) or the reverse order (C- > P). Perioperative cisplatin-based chemo was allowed if the interval between its completion and starting first-line mUC therapy was > 1 year. A multivariate analysis (MVA) examined the association of sequence of therapy with overall survival (OS) adjusted for baseline Hb ( C n = 33, C- > P n = 82) with median age 71, 74% men, and 85% ECOG PS 0-1 were included. Most pts (94.8%) had not received prior perioperative cisplatin-based chemo,...
- Subjects :
- 0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
First line
medicine.medical_treatment
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Internal medicine
medicine
Urothelial cancer
Cisplatin
Chemotherapy
business.industry
Perioperative
Carboplatin
Reverse order
stomatognathic diseases
030104 developmental biology
chemistry
030220 oncology & carcinogenesis
PD-L1 inhibitor
business
medicine.drug
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 36
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........d00f2b4109c5576aace97df7f6387c34